Is Ocean Rig UDW a good dividend stock to buy?
Ocean Rig UDW does not have a long track record of dividend growth. In the past three months, Ocean Rig UDW insiders have not sold or bought any company stock. 85.16% of the stock of Ocean Rig UDW is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Is Ocean Rig UDW a good buy at these PE ratios?
85.16% of the stock of Ocean Rig UDW is held by institutions. High institutional ownership can be a signal of strong market trust in this company. The P/E ratio of Ocean Rig UDW is 25.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.27.
Who is the CEO of Oric?
Chacko currently serves as President, CEO and member of the Board of Directors of ORIC Pharmaceuticals, Inc., (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments
How were Ocean Rig UDW's earnings last quarter?
Ocean Rig UDW Inc. (NASDAQ:ORIG) announced its quarterly earnings data on Thursday, August, 9th. The oil and gas company reported ($0.14) EPS for t...
When did Ocean Rig UDW's stock split? How did Ocean Rig UDW's stock split work?
Ocean Rig UDW's stock reverse split on Friday, September 22nd 2017. The 1-9200 reverse split was announced on Tuesday, September 19th 2017. The num...
Who are Ocean Rig UDW's key executives?
Ocean Rig UDW's management team includes the following people: Mr. Pankaj Khanna , Pres & CEO (Age 48) Mr. Anthony Kandylidis , Exec. Vice Chai...
Who are some of Ocean Rig UDW's key competitors?
Some companies that are related to Ocean Rig UDW include Helmerich & Payne (HP) , Valaris (VAL) , Patterson-UTI Energy (PTEN) , Baytex Energy (...
What other stocks do shareholders of Ocean Rig UDW own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ocean Rig UDW investors own include DryShips (DRYS) , Ens...
What is Ocean Rig UDW's stock symbol?
Ocean Rig UDW trades on the NASDAQ under the ticker symbol "ORIG."
What is Ocean Rig UDW's stock price today?
One share of ORIG stock can currently be purchased for approximately $27.78.
How much money does Ocean Rig UDW make?
Ocean Rig UDW (NASDAQ:ORIG) has a market capitalization of $2.53 billion and generates $1.01 billion in revenue each year.
What is Ocean Rig UDW's official website?
The official website for Ocean Rig UDW is www.ocean-rig.com .
About Ocean Rig UDW
Headlines
Ocean Rig UDW Inc., an offshore drilling contractor, provides oilfield services for offshore oil and gas exploration, development, and production drilling worldwide. It specializes in the ultra-deepwater and harsh-environment segment of the offshore drilling industry.
Ocean Rig UDW (NASDAQ:ORIG) Frequently Asked Questions
Thinking about trading options or stock in Transocean, American Airlines, Michaels Companies, Royal Caribbean Cruises, or Aurora Cannabis?
Component Grades
Ocean Rig UDW Inc. (NASDAQ:ORIG) released its quarterly earnings results on Thursday, August, 9th. The oil and gas company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.18 by $0.32.
Ocean Rig UDW Inc. - (ORIG) Company Bio
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
What is ORIC Pharmaceuticals?
Ocean Rig UDW Inc., an offshore drilling contractor, provides oilfield services for offshore oil and gas exploration, development, and production drilling. The company is based in Nicosia, Cyprus.
When is ORIC filing 10Q?
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 1:30 p.m. ET. A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event. About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer . ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn. Investor Contact:Dominic Piscitelli, Chief Financial [email protected]@oricpharma.com
When will ORIC 533 be released?
Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2020, and ORIC’s future reports to be filed with the SEC.
When will ORIC report 10K 2021?
and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Invest
What is the ORIC-101?
Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2021, and ORIC’s future reports to be filed with the SEC.